litlas
Log inCreate account

Jörge E. Cortes

Active 1991–2025

Also published as
Jorge E. Cortes
618
Papers
112,108
Citations
179
h-index
596
i10-index

Citations

Citations per year for Jörge E. Cortes1975: 1 citations1979: 12 citations1984: 1 citations1992: 1 citations1994: 1 citations1995: 1 citations1996: 2 citations1997: 8 citations1998: 10 citations1999: 20 citations2000: 31 citations2001: 52 citations2002: 134 citations2003: 285 citations2004: 326 citations2005: 306 citations2006: 489 citations2007: 678 citations2008: 699 citations2009: 816 citations2010: 845 citations2011: 807 citations2012: 841 citations2013: 870 citations2014: 834 citations2015: 927 citations2016: 961 citations2017: 852 citations2018: 875 citations2019: 3,220 citations2020: 3,658 citations2021: 3,431 citations2022: 2,605 citations2023: 1,984 citations2024: 3,379 citations2025: 1,401 citations2026: 19 citations1976–1978: no citations, so these years are not shown1980–1983: no citations, so these years are not shown1985–1991: no citations, so these years are not shown1993: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 7,515 citing papers, 29.6% of this breakdownChina: 2,100 citing papers, 8.3% of this breakdownGermany: 1,776 citing papers, 7% of this breakdownItaly: 1,616 citing papers, 6.3% of this breakdownUnited Kingdom: 1,491 citing papers, 5.9% of this breakdownFrance: 1,246 citing papers, 4.9% of this breakdownSpain: 786 citing papers, 3.1% of this breakdownCanada: 764 citing papers, 3% of this breakdownAustralia: 664 citing papers, 2.6% of this breakdownSwitzerland: 579 citing papers, 2.3% of this breakdownNetherlands: 567 citing papers, 2.2% of this breakdownJapan: 564 citing papers, 2.2% of this breakdown
0%29.6%Other 22.6%

Institutions

Fields

  • Medicine71.9%
  • Biochemistry, Genetics and Molecular Biology20.5%
  • Immunology and Microbiology3.3%
  • Materials Science0.9%
  • Computer Science0.8%
  • Chemistry0.7%
  • Other1.9%

Topics

  • Acute Myeloid Leukemia Research11.1%
  • Chronic Myeloid Leukemia Treatments7.9%
  • Chronic Lymphocytic Leukemia Research4.7%
  • Acute Lymphoblastic Leukemia research4.4%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment4.1%
  • Eosinophilic Disorders and Syndromes3.1%
  • Other64.7%

Coauthors

All papers

Open in search
  1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

    Authors: Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso‐Ramos, Jörge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström‐Lindberg, Gabriela Hobbs, Ronald Hoffman, Elias Jabbour, Jean‐Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte M. Niemeyer, Olatoyosi Odenike, Seishi Ogawa, Alberto Órfão, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching‐Hon Pui, Jerald P. Radich, Andreas Reiter, Marı́a Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt‐Graeff, Akiko Shimamura, Jorge Sierra, Wendy Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei‐Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi - Blood 2022 cited by 2,693

  2. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

    Authors: Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes, Andreas Neubauer, Ellin Berman, Stefania Paolini, Pau Montesinos, Maria R. Baer, Richard A. Larson, Celalettin Üstün, Francesco Fabbiano, Harry P. Erba, Antonio Di Stasi, Robert K. Stuart, Rebecca L. Olin, Margaret Kasner, Fabio Ciceri, Wen‐Chien Chou, Nikolai A. Podoltsev, Christian Récher, Hisayuki Yokoyama, Naoko Hosono, Sung‐Soo Yoon, Je‐Hwan Lee, Timothy S. Pardee, Amir T. Fathi, Chaofeng Liu, Nahla Hasabou, Xuan Liu, Erkut Bahceci, Mark J. Levis - New England Journal of Medicine 2019 cited by 1,239

  3. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Harry P. Erba, Pau Montesinos, Hee‐Je Kim, Elżbieta Patkowska, Radovan Vrḫovac, Pavel Žák, Po‐Nan Wang, Tsvetomir Mitov, James Hanyok, Yasser Mostafa Kamel, Jaime E Connolly Rohrbach, Li Liu, Aziz Benzohra, Arnaud Lesegretain, Jörge E. Cortes, Alexander E. Perl, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Mark J. Levis, Richard F. Schlenk - The Lancet 2023 cited by 366

  4. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

    Authors: Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Richard M. Stone, Dale L. Bixby, Jonathan E. Kolitz, Gary J. Schiller, Matthew J. Wieduwilt, Daniel H. Ryan, Antje Hoering, Kamalika Banerjee, Michael Chiarella, Arthur C. Louie, Bruno C. Medeiros - Journal of Clinical Oncology 2018 cited by 990

  5. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

    Authors: Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, Jane F. Apperley, André Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saußele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentín García‐Gutiérrez, Jörge E. Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus - Blood 2021 cited by 336

  6. Acute myeloid leukaemia

    Authors: Nicholas J. Short, Michael Rytting, Jörge E. Cortes - The Lancet 2018 cited by 781

  7. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

    Authors: Naval Daver, Guillermo Garcia‐Manero, Sreyashi Basu, Prajwal Boddu, Mansour Alfayez, Jörge E. Cortes, Marina Konopleva, Farhad Ravandi‐Kashani, Elias Jabbour, Tapan M. Kadia, Graciela M. Nogueras‐González, Jing Ning, Naveen Pemmaraju, Courtney D. DiNardo, Michael Andreeff, Sherry Pierce, Tauna Gordon, Steven M. Kornblau, Wilmer Flores, Zainab Alhamal, Carlos E. Bueso‐Ramos, Jeffrey L. Jorgensen, Keyur P. Patel, Jorge Blando, James P. Allison, Padmanee Sharma, Hagop M. Kantarjian - Cancer Discovery 2018 cited by 571

  8. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

    Authors: Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes, Hironobu Minami, Delphine Réa, Daniel J. DeAngelo, Massimo Breccia, Yeow-Tee Goh, Moshe Talpaz, Andreas Hochhaus, Philipp le Coutre, Oliver G. Ottmann, Michael C. Heinrich, Juan Luis Steegmann, Michael W. Deininger, Jeroen J. W. M. Janssen, François-Xavier Mahon, Yosuke Minami, David T Yeung, David M. Ross, Martin S. Tallman, Jae H. Park, Brian Druker, David Hynds, Yuyan Duan, Christophe Meille, Florence Hourcade‐Potelleret, K. Gary J. Vanasse, Fabian Lang, Dong‐Wook Kim - New England Journal of Medicine 2019 cited by 467

  9. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Authors: Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Siu‐Fun Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M. Goldman, Neil P. Shah, Hagop M. Kantarjian - New England Journal of Medicine 2013 cited by 1,124

  10. Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

    Authors: Rongqing Pan, Leah J. Hogdal, Juliana M. Benito, Donna Bucci, Lina Han, Gautam Borthakur, Jörge E. Cortes, Daniel J. DeAngelo, LaKeisha Debose, Hong Mu, Hartmut Döhner, Verena I. Gaidzik, Ilene Galinsky, Leonard S. Golfman, Torsten Haferlach, Karine G. Harutyunyan, Jianhua Hu, Joel D. Leverson, Guido Marcucci, Markus Müschen, Rachel Newman, Eugene Park, Peter P. Ruvolo, Vivian Ruvolo, Jeremy Ryan, Sonja Schindela, Patrick A. Zweidler‐McKay, Richard M. Stone, Hagop M. Kantarjian, Michael Andreeff, Marina Konopleva, Anthony Letai - Cancer Discovery 2013 cited by 735

  11. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Authors: Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian - Blood 2018 cited by 583

  12. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

    Authors: Kiyomi Morita, Feng Wang, Katharina Jahn, Tianyuan Hu, Tomoyuki Tanaka, Yuya Sasaki, Jack Kuipers, Sanam Loghavi, Sa A. Wang, Yuanqing Yan, Ken Furudate, Jairo Matthews, Latasha Little, Curtis Gumbs, Jianhua Zhang, Xingzhi Song, Erika J. Thompson, Keyur P. Patel, Carlos E. Bueso‐Ramos, Courtney D. DiNardo, Farhad Ravandi, Elias Jabbour, Michael Andreeff, Jörge E. Cortes, Kapil N. Bhalla, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Marina Konopleva, Daisuke Nakada, Nicholas E. Navin, Niko Beerenwinkel, P. Andrew Futreal, Koichi Takahashi - Nature Communications 2020 cited by 387

  13. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

    Authors: Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian, Michele Baccarani, Jiřı́ Mayer, Concepción Boqué, Neil P. Shah, Charles Chuah, Luís Casanova, Brigid Bradley-Garelik, George Manos, Andreas Hochhaus - Journal of Clinical Oncology 2016 cited by 946

  14. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

    Authors: Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jörge E. Cortes, Timothy P. Hughes, Jane F. Apperley, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, André Abdo, Laura Fogliatto, Philipp le Coutre, Koji Sasaki, Dennis Dong Hwan Kim, Susanne Saußele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, Valentín García‐Gutiérrez, S. S. Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J. Mauro - Leukemia 2023 cited by 135

  15. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

    Authors: Stéphane de Botton, Pierre Fenaux, Karen Yee, Christian Récher, Andrew H. Wei, Pau Montesinos, David Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Ollivier Legrand, Pierre Péterlin, Montserrat Arnán, William Blum, Daniela Cilloni, Devendra Hiwase, Joseph G. Jurcic, Jürgen Krauter, Xavier Thomas, Justin M. Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jörge E. Cortes - Blood Advances 2023 cited by 124

  16. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

    Authors: Animesh Pardanani, Claire Harrison, Jörge E. Cortes, Francisco Cervantes, Ruben A. Mesa, Donald Milligan, Tamás Masszi, Elena Mishchenko, Éric Jourdan, Alessandro M. Vannucchi, Mark W. Drummond, Mindaugas Jurgutis, Kazimierz Kuliczkowski, Emanuil Gheorghita, Francesco Passamonti, Frank Neumann, Abhay Patki, Guozhi Gao, Ayalew Tefferi - JAMA Oncology 2015 cited by 472

  17. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

    Authors: Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah, Dong‐Wook Kim, Iryna Dyagil, Nataliia Glushko, Dragana Milojković, Philipp le Coutre, Valentín García‐Gutiérrez, Laurence Reilly, Allison Jeynes-Ellis, Eric Leip, Nathalie Bardy‐Bouxin, Andreas Hochhaus, Tim H. Brümmendorf - Journal of Clinical Oncology 2017 cited by 493

  18. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

    Authors: Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli, Alexander E. Perl, Siddhartha Ganguly, Nigel H. Russell, Alwin Krämer, Hervé Dombret, Donna E. Hogge, Brian A. Jonas, Anskar Y.H. Leung, Priyanka Mehta, Pau Montesinos, Markus P. Radsak, Simona Sica, Meena Arunachalam, Melissa F. Holmes, Ken Kobayashi, Ruth Namuyinga, Nanxiang Ge, Antoine Yver, Yufen Zhang, Mark J. Levis - The Lancet Oncology 2019 cited by 479

  19. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

    Authors: Jörge E. Cortes, Jane F. Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Arthur, Lori J. Maness, Moshe Talpaz, Michael J. Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger - Blood 2021 cited by 193

  20. The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

    Authors: Patrick Williams, Sreyashi Basu, Guillermo Garcia‐Manero, Christopher S. Hourigan, Karolyn A. Oetjen, Jörge E. Cortes, Farhad Ravandi, Elias Jabbour, Zainab Alhamal, Marina Konopleva, Jing Ning, Lianchun Xiao, Juliana Hidalgo Lopez, Steve Kornblau, Michael Andreeff, Wilmer Flores, Carlos E. Bueso‐Ramos, Jorge Blando, Pallavi Galera, Katherine R. Calvo, Gheath Alatrash, James P. Allison, Hagop M. Kantarjian, Padmanee Sharma, Naval Daver - Cancer 2018 cited by 341

  21. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

    Authors: Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prébet, Sang‐Min Lee, Gary J. Schiller, Shira Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang, Karen Seiter, Andrew H. Wei, Stéphane de Botton, Montserrat Arnán, Will Donnellan, Anthony P. Schwarer, Christian Récher, Brian A. Jonas, P. Brent Ferrell, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M. Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jörge E. Cortes - The Lancet Haematology 2022 cited by 117

  22. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

    Authors: Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Dale L. Bixby, Jonathan E. Kolitz, Gary J. Schiller, Matthew J. Wieduwilt, Daniel Ryan, Stefan Faderl, Jörge E. Cortes - The Lancet Haematology 2021 cited by 211

  23. Mutations in AML: prognostic and therapeutic implications

    Authors: Courtney D. DiNardo, Jörge E. Cortes - Hematology 2016 cited by 265

  24. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

    Authors: Abhishek Maiti, Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi, Guillermo Garcia‐Manero, Gautam Borthakur, Kiran Naqvi, Maro Ohanian, Nicholas J. Short, Yesid Alvarado, Tapan M. Kadia, Koichi Takahashi, Musa Yılmaz, Nitin Jain, Steven M. Kornblau, Guillermo Montalban‐Bravo, Koji Sasaki, Michael Andreeff, Prithiviraj Bose, Alessandra Ferrajoli, Ghayas C. Issa, Elias Jabbour, Lucia Masárová, Philip A. Thompson, Sa Wang, Sergej Konoplev, Sherry Pierce, Jing Ning, Wei Qiao, John S. Welch, Hagop M. Kantarjian, Courtney D. DiNardo, Marina Konopleva - Haematologica 2020 cited by 173